The European Medicines Agency has recommended for pan-EU marketing approval eight new drugs, including Rhythm Pharmaceuticals’ obesity treatment, Imcivree (setmelanotide), and Albireo Pharma’s liver disease drug, Bylvay (odevixibat).
If approved by the European Commission, Imcivree will be the first treatment in the EU for obesity caused by certain...








